2023-03-22 09:00:04 ET
- Wuxi Biologics ADR press release ( OTCPK:WXXWY ): FY Non-GAAP EPS of RMB1.13.
- Revenue of RMB15.27B (+48.4% Y/Y).
For further details see:
Wuxi Biologics ADR Non-GAAP EPS of RMB1.13, revenue of RMB15.27Bhome / stock / wxxwy / wxxwy news
2023-03-22 09:00:04 ET
For further details see:
Wuxi Biologics ADR Non-GAAP EPS of RMB1.13, revenue of RMB15.27BMarket Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
News, Short Squeeze, Breakout and More Instantly...
Wuxi Biologics Cayman Inc ADR Company Name:
WXXWY Stock Symbol:
Market:
WuXi Biologics Named Constituent of the FTSE4Good Index Series for Fourth Year PR Newswire SHANGHAI , July 10, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), anno...
WuXi Biologics Successfully Implemented a Fully Integrated Continuous Process with a Breakthrough Productivity of ~6 g/L/day at Pilot Scale PR Newswire By leveraging WuXiUP TM , WuXi Biologics has completed its first end-to-end continuous drug substance (DS) manufacturing ...
WuXi Biologics Receives AAA MSCI ESG Rating PR Newswire SHANGHAI , Nov. 7, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has received an AAA rating ...